Acorda Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile


Ardsley, NY USA
Total Funding:$156.6M
Lead Investor(s):N/A

Estimated Revenue & Financials

  • Acorda Therapeutics's total funding is $156.6M.

Employee Data

  • Acorda Therapeutics has 608 Employees.(?)
  • Acorda Therapeutics currently has 1 job openings.

Acorda Therapeutics, a privately held biotechnology company, is developing therapies for spinal cord injury (SCI) and related neurological conditions, including multiple sclerosis (MS). The Company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and Phase 2 for MS. Acorda's technology platform includes two remyelinating agents in preclinical development for MS. They include M1, a class of human monoclonal antibodies, and GGF2, a product of the neuregulin 1 gene. Both agents have been shown to restore myelin in the brain and spinal cord in animal models of MS. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain. In 2002, Acorda was the recipient of the National Spinal Cord Injury Association's L. W. Freeman Award for scientific research.